Adalimumab

Summary

Adalimumab (CHEMBL1201580) is an approved antibody (ATC L04AB04); indicated across 37 conditions including ankylosing spondylitis and psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AB04
• Indications: 37 conditions
• Clinical trials: 443

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201580
Name	Adalimumab
Type	Antibody
Max phase	4
ATC	L04AB04

Also known as: Abp-501, Abrilada, Adalimumab, Adalimumab (abbvie), Adalimumab (genetical recombination), Adalimumab (humira), Adalimumab aacf, Adalimumab adaz, Adalimumab adbm, Adalimumab afzb, Adalimumab aqvh, Adalimumab atto

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
ankylosing spondylitis	4	MONDO:0005306	EFO:0003898
psoriasis	4	MONDO:0005083	EFO:0000676
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
ulcerative colitis	4	MONDO:0005101	EFO:0000729
Crohn disease	4	MONDO:0005011	EFO:0000384
psoriatic arthritis	4	MONDO:0011849	EFO:0003778
juvenile idiopathic arthritis	4	MONDO:0011429	EFO:0002609
hidradenitis suppurativa	4	MONDO:0006559	EFO:1000710
uveitis	4	MONDO:0020283	EFO:1001231
immune system disorder	4	MONDO:0005046	EFO:0000540
arthritic joint disease	4	MONDO:0005578	EFO:0005856
psoriasis-related juvenile idiopathic arthritis	4	MONDO:0019436	EFO:0009733

22 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pyoderma	3	MONDO:0002922	HP:0000999
Behcet disease	3	MONDO:0007191	EFO:0003780
temporal arteritis	3	MONDO:0008538	EFO:1001209
interstitial cystitis	3	MONDO:0018301	EFO:0008507
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
inflammatory bowel disease	3	MONDO:0005265	EFO:0003767
osteoarthritis	3	MONDO:0005178	MONDO:0005178
spondyloarthropathy	3	MONDO:0005095	EFO:0000706
focal segmental glomerulosclerosis	2	MONDO:0100313	EFO:0004236
colitis	2	MONDO:0005292	EFO:0003872
palmar fibromatosis	2	MONDO:0006345	EFO:0004229
sciatica	2	MONDO:0024333	HP:0011868
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616
frozen shoulder	2	MONDO:0006763	EFO:1000941
asthma	2	MONDO:0004979	MONDO:0004979
Netherton syndrome	2	MONDO:0009735	MONDO:0009735
sarcoidosis	2	MONDO:0019338	MONDO:0019338
benign prostatic hyperplasia	2	MONDO:0010811	EFO:0000284
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
choroidal neovascularization	2	MONDO:0810000	MONDO:0810000
mucopolysaccharidosis type 6	1	MONDO:0009661	MONDO:0009661
mucopolysaccharidosis type 2	1	MONDO:0010674	MONDO:0010674

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 443.

Phase distribution

Phase	Trials
PHASE3	156
PHASE4	103
PHASE2	68
Not specified	68
PHASE1	33
PHASE2/PHASE3	9
PHASE1/PHASE2	5
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03917303	PHASE4	RECRUITING	Control Crohn Safe Trial
NCT04183608	PHASE4	RECRUITING	A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
NCT04300686	PHASE4	RECRUITING	A Pilot Study in Severe Patients With Takayasu Arteritis.
NCT04646187	PHASE4	ENROLLING_BY_INVITATION	De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
NCT05626348	PHASE4	RECRUITING	The Clinical Efficacy of Immunomodulators in RA Patients
NCT06045754	PHASE4	RECRUITING	A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn’s Disease
NCT06180382	PHASE4	RECRUITING	Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn’s Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06390436	PHASE4	NOT_YET_RECRUITING	Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
NCT06498089	PHASE4	RECRUITING	A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu’s Arteritis
NCT06527534	PHASE4	RECRUITING	Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
NCT06833112	PHASE4	NOT_YET_RECRUITING	Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT07013838	PHASE4	NOT_YET_RECRUITING	The Efficacy and Safety of Deucravacitinib in Takayasu’s Arteritis
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07510191	PHASE4	RECRUITING	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn’s Disease With Suboptimal Response
NCT07529925	PHASE4	NOT_YET_RECRUITING	A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
NCT07564505	PHASE4	NOT_YET_RECRUITING	Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn’s Disease
NCT00133315	PHASE4	COMPLETED	TNFalfa Blocking Treatment of Spondylarthropathies
NCT00216177	PHASE4	UNKNOWN	Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
NCT00234234	PHASE4	COMPLETED	Predictors of the Response to Adalimumab in Rheumatoid Arthritis
NCT00234897	PHASE4	COMPLETED	Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis
NCT00291915	PHASE4	UNKNOWN	Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis
NCT00420927	PHASE4	COMPLETED	Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
NCT00477893	PHASE4	UNKNOWN	Danish Multicenter Study of Adalimumab in Spondyloarthritis
NCT00480272	PHASE4	COMPLETED	Prospective Study on Intensive Early Rheumatoid Arthritis Treatment
NCT00517296	PHASE4	COMPLETED	Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn’s Perianal Fistulas
NCT00649922	PHASE4	COMPLETED	Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis
NCT00696059	PHASE4	COMPLETED	Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?
NCT00735787	PHASE4	COMPLETED	Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
NCT00761514	PHASE4	TERMINATED	Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira
NCT00796705	PHASE4	TERMINATED	Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00808509	PHASE4	COMPLETED	A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
NCT00837434	PHASE4	COMPLETED	Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
NCT00932113	PHASE4	COMPLETED	Mechanism of Action Study for Psoriasis
NCT00940862	PHASE4	COMPLETED	Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis
NCT00972218	PHASE4	WITHDRAWN	Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
NCT01000441	PHASE4	COMPLETED	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
NCT01029847	PHASE4	COMPLETED	Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
NCT01072058	PHASE4	UNKNOWN	Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
NCT01119859	PHASE4	COMPLETED	A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
NCT01162421	PHASE4	COMPLETED	A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
NCT01174186	PHASE4	COMPLETED	Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
NCT01181570	PHASE4	COMPLETED	Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea
NCT01185288	PHASE4	COMPLETED	A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
NCT01237262	PHASE4	UNKNOWN	Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy
NCT01265823	PHASE4	COMPLETED	Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
NCT01270035	PHASE4	UNKNOWN	Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate
NCT01270087	PHASE4	COMPLETED	The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.
NCT01283971	PHASE4	TERMINATED	A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
NCT01295151	PHASE4	COMPLETED	SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
NCT01382160	PHASE4	COMPLETED	Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)
NCT01405326	PHASE4	UNKNOWN	REstore Working Ability in RheumatoiD Arthritis
NCT01465438	PHASE4	COMPLETED	HUmira in Psoriatic Arthritis
NCT01500278	PHASE4	COMPLETED	Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
NCT01553058	PHASE4	COMPLETED	Vascular Inflammation in Psoriasis Trial (The VIP Trial)
NCT01556672	PHASE4	COMPLETED	Adalimumab-psoriasis and Small Bowel Lesions
NCT01602302	PHASE4	TERMINATED	Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
NCT01609205	PHASE4	COMPLETED	Doppler Evaluation in RA Patients After Adalimumab.
NCT01644396	PHASE4	COMPLETED	An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
NCT01722214	PHASE4	COMPLETED	Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
NCT01793519	PHASE4	UNKNOWN	Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis
NCT01866592	PHASE4	COMPLETED	Vascular Inflammation in Psoriasis - Extension Study
NCT01893996	PHASE4	COMPLETED	Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease
NCT01895764	PHASE4	COMPLETED	Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)
NCT02035800	PHASE4	UNKNOWN	Bone Resorption, Osteoclastogenesis and Adalimumab
NCT02056184	PHASE4	COMPLETED	Targeted Ultrasound in Rheumatoid Arthritis
NCT02092467	PHASE4	COMPLETED	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
NCT02132234	PHASE4	UNKNOWN	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
NCT02148718	PHASE4	COMPLETED	Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NCT02198651	PHASE4	COMPLETED	A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
NCT02256462	PHASE4	COMPLETED	Pediatric Crohn’s Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
NCT02374021	PHASE4	COMPLETED	Treatments Against RA and Effect on FDG-PET/CT
NCT02451748	PHASE4	COMPLETED	IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02489760	PHASE4	UNKNOWN	Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study
NCT02492217	PHASE4	COMPLETED	Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent’s Efficacy in Ankylosing Spondylitis Patients
NCT02557100	PHASE4	COMPLETED	Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
NCT02634541	PHASE4	UNKNOWN	Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis
NCT02764762	PHASE4	COMPLETED	Triple Combination Therapy in High Risk Crohn’s Disease (CD)
NCT02808975	PHASE4	COMPLETED	Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
NCT02814175	PHASE4	COMPLETED	A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
NCT02852694	PHASE4	COMPLETED	Reduce Risk for Crohn’s Disease Patients
NCT02878161	PHASE4	UNKNOWN	Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World
NCT02897115	PHASE4	TERMINATED	A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
NCT03059849	PHASE4	WITHDRAWN	Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD
NCT03100253	PHASE4	TERMINATED	Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation
NCT03151551	PHASE4	COMPLETED	A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
NCT03220841	PHASE4	UNKNOWN	Stricture Definition and Treatment (STRIDENT) Drug Therapy Study
NCT03221621	PHASE4	UNKNOWN	Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
NCT03505008	PHASE4	COMPLETED	Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan
NCT03619876	PHASE4	TERMINATED	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
NCT03737708	PHASE4	COMPLETED	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
NCT03739853	PHASE4	COMPLETED	Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
NCT03816397	PHASE4	COMPLETED	Adalimumab in JIA-associated Uveitis Stopping Trial
NCT04132388	PHASE4	WITHDRAWN	Hidradenitis Suppurativa Patient Experience With Humira Treatment
NCT04194827	PHASE4	UNKNOWN	Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring
NCT04222920	PHASE4	COMPLETED	Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity
NCT04255134	PHASE4	COMPLETED	Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
NCT05015335	PHASE4	UNKNOWN	The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage
NCT05151848	PHASE4	UNKNOWN	Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
NCT05153200	PHASE4	UNKNOWN	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
NCT05164198	PHASE4	UNKNOWN	REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).